Nautilus Biotechnology (NAUT) Free Cash Flow (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Free Cash Flow of -$14.2 million for Q2 2026, down 4.19% sequentially from -$13.6 million in Q1 2026, and down 3.16% YoY from -$14.6 million in Q2 2025.
Nautilus Biotechnology (NAUT) Free Cash Flow (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Free Cash Flow for 7 years, with the latest figure at -$14.2 million in Q2 2026.
- Quarterly Free Cash Flow fell 3.16% year-over-year to -$14.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$51.9 million (up 7.86% YoY) and the FY2025 annual result came in at -$52.0 million, up 15.17% from the prior year.
- Free Cash Flow eased to -$14.2 million in Q2 2026 per NAUT's latest filing, from -$13.6 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$10.5 million in Q3 2022 and troughed at -$16.9 million in Q1 2024.
- A 5-year average of -$13.5 million and a median of -$13.8 million in 2024 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 27.13% in 2022, down 90.29% in 2022.
- Over 5 years, Free Cash Flow stood at -$10.6 million in 2022, then slumped by 34.95% to -$14.3 million in 2023, then declined by 1.75% to -$14.6 million in 2024, then increased by 13.35% to -$12.6 million in 2025, then retreated by 12.37% to -$14.2 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$14.2 million, -$13.6 million, and -$12.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | -14.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.18 Mn |
| Jun 30, 2026 | -14.18 Mn |
| Mar 31, 2026 | -13.61 Mn |
| Mar 31, 2026 | -13.61 Mn |
| Dec 31, 2025 | -12.62 Mn |
| Dec 31, 2025 | -12.62 Mn |
| Sep 30, 2025 | -11.45 Mn |
| Sep 30, 2025 | -11.45 Mn |
| Jun 30, 2025 | -13.75 Mn |
| Jun 30, 2025 | -13.75 Mn |
| Mar 31, 2025 | -14.16 Mn |
| Mar 31, 2025 | -14.16 Mn |
| Dec 31, 2024 | -14.56 Mn |
| Dec 31, 2024 | -14.56 Mn |
| Sep 30, 2024 | -13.82 Mn |
| Sep 30, 2024 | -13.82 Mn |
| Jun 30, 2024 | -15.97 Mn |
| Jun 30, 2024 | -15.97 Mn |
| Mar 31, 2024 | -16.91 Mn |
| Mar 31, 2024 | -16.91 Mn |